UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Operating revenue:
Personalized oncology solutions	$ 439,000	$ 511,000
Translational oncology solutions	4,594,000	3,159,000
Total operating revenue	5,033,000	3,670,000
Costs and operating expenses:
Cost of personalized oncology solutions	387,000	474,000
Cost of translational oncology solutions	2,255,000	2,049,000
Research and development	1,118,000	1,211,000
Sales and marketing	683,000	925,000
General and administrative	1,209,000	1,534,000
Total costs and operating expenses	5,652,000	6,193,000
Loss from operations	(619,000)	(2,523,000)
Other (expense):
Other (expense)	(51,000)	(9,000)
Total other (expense)	(51,000)	(9,000)
Loss before provision for income taxes	(670,000)	(2,532,000)
Provision for income taxes	4,000	14,000
Net loss	$ (674,157)	$ (2,546,449)
Net loss per common share outstanding
Net loss per common share outstanding, basic and diluted (in dollars per share)	$ (0.06)	$ (0.26)
Weighted average common shares outstanding
Weighted average common shares outstanding, basic and diluted (in shares)	10,982,159	9,835,279